MDFM News: PROSTATE CANCER at ASCO GU: 18 months of androgen blockade as safe and effective as 36 months in node-negative high-risk patients

MDFM News: PROSTATE CANCER at ASCO GU: 18 months of androgen blockade as safe and effective as 36 months in node-negative high-risk patients

0:00
27 February 2013

Other headlines: – Raised incidence of HPV-associated cancers in the past 35 years in the United States. – Two new anticoagulants for the extended treatment of patients with unprovoked ven

Other headlines:
– Raised incidence of HPV-associated cancers in the past 35 years in the United States.

– Two new anticoagulants for the extended treatment of patients with unprovoked venous thromboembolism.

– Opioid analgesics drove increase in drug overdose deaths in 2010.

– Respiratory symptoms vary throughout menstrual cycle.

– Smoking bans in Belgium associated with reductions in risks of preterm delivery.

– Hydroxyethyl starch associated with a greater risk of death and acute kidney injury in critically ill patients requiring volume resuscitation.

Related Episodes

Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls

Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls

The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies.  I’m Peter Goodwin wi

1 October 2025
6:07
More
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025

Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025

Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)

30 June 2025
11:51
More
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy

Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy

An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon

10 June 2025
7:24
More